Heart Test Laboratories Inc. Common Stock (HSCS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Heart Test Laboratories Inc. Common Stock (HSCS) has a cash flow conversion efficiency ratio of -558.107x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.33 Billion) by net assets ($4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Heart Test Laboratories Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Heart Test Laboratories Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read HSCS total debt and obligations for a breakdown of total debt and financial obligations.
Heart Test Laboratories Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Heart Test Laboratories Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bernard Loisea
PA:ALDBL
|
0.144x |
|
Zimtu Capital Corp
V:ZC
|
-0.009x |
|
Culpeo Minerals Ltd
AU:CPO
|
-0.105x |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
-0.002x |
|
Minaean SP Construction Corp
V:MSP
|
-1.154x |
|
Iceni Gold Ltd
AU:ICL
|
-0.017x |
|
Enova Mining Ltd
AU:ENV
|
-0.031x |
|
Djasa Ubersakti Tbk
JK:PTDU
|
-5.449x |
Annual Cash Flow Conversion Efficiency for Heart Test Laboratories Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Heart Test Laboratories Inc. Common Stock from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Heart Test Laboratories Inc. Common Stoc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $205.17K | $-7.41 Million | -36.131x | -4255.39% |
| 2024-04-30 | $7.32 Million | $-6.07 Million | -0.830x | +96.69% |
| 2023-04-30 | $230.56K | $-5.77 Million | -25.042x | -4261.43% |
| 2022-04-30 | $-6.06 Million | $-3.64 Million | 0.602x | -53.14% |
| 2021-04-30 | $-1.91 Million | $-2.45 Million | 1.284x | +110.55% |
| 2020-04-30 | $315.55K | $-3.84 Million | -12.169x | -- |
About Heart Test Laboratories Inc. Common Stock
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting… Read more